Skip to main content
. 2014 Jul 8;9(7):e101819. doi: 10.1371/journal.pone.0101819

Figure 4. Overall survival in non-high-dose treated (non-HDT) patients with and without renal impairmet treated with novel agents.

Figure 4

(A) Patients with renal impairment compared to those without renal impairment after the use of novel agents (bortezomib, lenalidomide or thalidomide) in the 1st treatment line. (B) Patients with renal impairment compared to those without renal impairment after the use of bortezomib in the 1st treatment line.